Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028 Report Analysis and Data Highlights:
- Research Methodology
- Global and Regional Market Analysis
- Global Bispecific Antibody Market Opportunity Assessment: > USD 20 Billion
- Market and Drug Sales Insight 2020 Till 2028
- Approved Drug In Market: 3 Drugs
- Approved Bispecific Antibody Drug Patent, Price and Sales insight 2020 Till 2028
- Future Market Assessment By Indication Till 2028
- Ongoing Clinical Trials Assessment by Status, Phase and Region
- Key Market Dynamics
- Competitor Landscape
Download Report:
The revolutionary trend in the era of antibody therapeutics is brought by the development of bispecific antibodies. These novel antibodies have dual specificity which enables them to bind to two different molecular targets at the same time. As cancer is multifactorial disease, these bispecific antibodies are employed for the management of cancer. Researchers have recently developed bispecific T-cell engagers which are novel subclass of bispecific antibodies which act by polyclonal activation and engaging the entire cytotoxic T-cells brigade to tumor cells.
Bilnatumomab, sold under brand name Blincyto is first representative of bispecific T-cell engager. The drug was developed by Amgen and is indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The drug is bispecific CD19-directed CD3 T-cell engager that binds to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells. Blinatumomab mediates the formation of a synapse between the T cell and the tumor cell, upregulation of cell adhesion molecules, production of cytolytic proteins, release of inflammatory cytokines, and proliferation of T cells, which result in redirected lysis of CD19+ cells.
Since the entry of first bispecific T cell engager in 2014, the drug has shown high adoption rates in market owing to its novel mechanism of action and high specificity towards cancer cell. In addition, these drugs have shown to overcome the limitations of conventional cancer therapies as well as other monoclonal antibodies. Due to their multifactorial approach of these molecules i.e. a single molecule can heal more than one disease making the affair more profitable and interesting for the developers. The ability of binding dual signaling pathways or gene simultaneously has also shown high potency in targeting cancers.
The main challenge for the approved bispecific antibody was the low shelf life of the molecule which requires repeated doses of drug at regular interval. Keeping this in mind, several pharmaceutical companies like Amgen are designing half-life extended bispecific T-cell engagers which may solve the problem of repeated infusions. These are in clinical development and may appear as novel molecules in near future. AMG-701 is an investigational half-life extended (HLE) bispecific T cell engager immuno-oncology therapy targeting B-cell maturation antigen (BCMA). The emerging data from phase-I clinical trial is highly encouraging and suggests promising future of bispecific antibodies in wide range of cancers.
Through analysis of market in respect to opportunities, bispecific T-cell engagers are expected to lead other sectors also such as cardinology. With the enthusiastic participation of biotech companies, the market is going to be spurred with novel bispecific T-cell engagers. The major key players in market are Amgen, Novartis, Pfizer, Roche and Bayer. With the increased demand of targeted therapy, it is expected that novel therapies will completely take over the conventional treatment in future.
The report Bispecific T-cell Engagers suggests that the market is poised to grow in coming years. The coming years is expected to witness large number of product approvals in several cancers, which will propel the growth of market. Another reason for the high demand of these novel antibodies is driven by the fact that cancer has become one of the leading causes of deaths worldwide which is mainly due to adoption of sedentary lifestyle. The high mortality and morbidity associated with cancer is mainly due to lack of completely curing drugs available in market. The increasing number of cancer patients call for the urgent development of novel treatment methods to treat them. North America, particularly US is the leading regional market which is mainly due to high incidences of the disease along with rising awareness among the individuals about the availability of novel therapies in managing them.
Contact:
Neeraj Chawla
Research Head
+91-9810410366